

1 A novel labelling strategy enables spatial resolution of the lung metastatic niche and
2 uncovers tissue stem cell-like features proximal to breast cancer cells

3

4 Luigi Ombrato¹, Emma Nolan¹, Ivana Kurelac^{1,3}, Antranik Mavousian², Victoria Bridgeman¹,
5 Probir Chakravarty⁴, Stuart Horswell⁴, Ivonne Heinze⁵, Estela Gonzales-Gualda¹, Giulia
6 Matacchione¹, Anne Weston⁶, Joanna Kirkpatrick⁵, Ehab Husain⁷, Valerie Speirs⁸, Lucy
7 Collinson⁶, Alessandro Ori⁵, Joo-Hyeon Lee^{2*}, Ilaria Malanchi^{1*}

8

9 *1 Tumour Host Interaction laboratory, The Francis Crick Institute, 1 Midland Road, NW1 1AT London; 2 Wellcome*
10 *Trust/Medical Research Council Stem Cell Institute, University of Cambridge, Tennis Court Road, Cambridge CB2*
11 *1QR, UK; 3 Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Via Massarenti 9, 40138*
12 *Bologna, Italy; 4 Bioinformatics & Biostatistics Unit, The Francis Crick Institute, 1 Midland Road, NW1 1AT London;*
13 *6 Electron Microscopy Unit, The Francis Crick Institute, 1 Midland Road, NW1 1AT London; 5 Proteomics of aging,*
14 *Leibniz Institute on Aging, Fritz Lipmann Institute (FLI) Beutenbergstrasse 11, 07745 Jena, Germany; 7 Department*
15 *of Pathology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, AB25 2ZN, Scotland, UK; 8 Institute of Medical*
16 *Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, Scotland, UK.*

17 **Corresponding authors: Ilaria Malanchi (Ilaria.Malanchi@crick.ac.uk) and Joo-Hyeon Lee (jhl62@cam.ac.uk).*

18

19 Cancer cell behaviour is strongly influenced by the surrounding cellular environment, making
20 the characterisation of the local tumour microenvironment (or niche) a fundamental question
21 in tumour biology. To date, a direct investigation of the early cellular changes induced by
22 metastatic cells within the surrounding tissue is difficult to achieve, especially at early micro-
23 metastatic stages and for low frequency populations present in the niche. Here we present the
24 strategy whereby metastatic cancer cells release a cell-penetrating fluorescent protein that is
25 efficiently taken up by neighbouring cells, allowing spatial identification of the local metastatic
26 cellular environment within the whole tissue. Notably, this strategy can be used to follow
27 metastatic niches from early micro-metastasis to late macro-metastasis, allowing temporal
28 resolution. Moreover, the presence of low represented niche cells can be detected and
29 characterised among the bulk tissue. To highlight the potential of this niche-labelling strategy,
30 we have applied this system to the study the lung metastatic environment of breast cancer
31 cells. We report the unprecedented presence of cancer parenchymal associated cells (CAPs)
32 within the lung metastatic niche, where lung epithelial cells show stem cell-like features with
33 expression of lung progenitor markers, multilineage differentiation potential and self-renewal
34 activity. Moreover, lung epithelial cells are directly perturbed by cancer cells in *ex vivo* co-
35 culture assays and support their growth. In summary, here we describe a novel labelling
36 system that enables spatial resolution of the metastatic microenvironment and provide
37 evidence that the tissue cellular environment surrounding metastatic growth is characterised

38 by undifferentiated features. The data highlight the significant potential of this method as a
39 platform for new discoveries.

40
41 During the early phase of metastatic growth, cancer cells generate a local tissue
42 microenvironment (metastatic niche), which is very distinct from the normal tissue structure
43 and key to support their survival and growth¹. However, a detailed analysis of the cellular
44 composition of the metastatic niche, especially at early stages, is significantly constrained by
45 the difficulty to spatially discriminate the cells in the metastatic niche from the bulk of the tissue.
46 This hampers identification of tissue cells that might respond to the early cancer infiltration but
47 remain less represented when metastases grow bigger.

48 To overcome these limitations, we developed a system whereby metastatic cancer cells
49 directly mark their neighbouring cells by releasing a modified version of a secreted monomeric
50 Cherry red fluorescent protein (mCherry) containing a lipo-permeable TATk peptide^{2,3} (sLP-
51 mCherry) (Figure 1a and Extended Data Figure 1a). We generated 4T1 breast cancer cells
52 expressing the sLP-mCherry protein alongside a canonical cell-retained GFP, which we refer
53 to as Labelling-4T1. *In vitro*, sLP-mCherry protein released by Labelling-4T1 is re-up-taken
54 within producing cells as observed by changes in the intracellular localisation of the red
55 fluorescence (Extended Data Figure 1b, c). Importantly, sLP-mCherry protein is also taken up
56 by unlabelled cells both in co-culture (Figure 1b-d) and when cultured with Labelling-4T1
57 conditioned medium (LCM) (Extended Data Figure 1d, e). Upon uptake, sLP-mCherry
58 fluorescence has an intracellular half-life of 43h (Extended Data Figure 1f) and is localized in
59 intracellular vesicles (IVs) which are CD63⁺ multi-lamellar bodies (lysosomal-like structures).
60 Due to its high photostability⁴, mCherry retains high fluorescent intensity (Extended Data
61 Figure 1g, h). LCM fractionation shows that only the soluble fraction displays labelling activity,
62 while the extracellular vesicles (EVs), a portion of which contains sLP-mCherry, do not show
63 *in vitro* labelling activity (Extended Data Figure 1i-k). Critically, *in vivo*, Labelling-4T1 cells
64 (GFP/Cherry double positive) intravenously injected into syngeneic BALB/c mice efficiently
65 label their surrounding host tissue cells (Cherry single positive), with a penetration of
66 approximately five cell layers (Figure 1e, f and Extended Data Figure 2a, b). This allows
67 metastatic niche cells to be specifically discriminated from the distal lung (GFP/Cherry double
68 negative) using fluorescent activated cell sorting (FACS) (Figure 1g). Notably, when
69 metastases form, the number of mCherry⁺ niche cells in the tissue remains proportional to the
70 growing metastatic cells (Extended Data Figure 2c). We detected no immunogenicity against
71 sLP-mCherry, since the local increase of CD45⁺ immune cells within the mCherry population
72 was independent from the adaptive immune system and was observed specifically as a
73 response to cancer cells (Extended Data Figure 2d-f). Hence, the *Cherry-niche* marking
74 system (Cherry-niche) enables the spatial reconstitution of the local metastatic niche within

75 the whole tissue. This allows functional identification of labelled cells (Cherry-niche cells) and
76 their direct comparison with the remaining unlabelled tissue cells within the same lung.

77 We first aimed to validate Cherry-niche by interrogating the local changes of known cells
78 involved in niche formation. We focused on the micro-metastatic stage, where metastases are
79 small, but established and therefore likely to have settled a successful metastatic niche. CD45⁺
80 immune cells are the most abundant component within Cherry-niche, which are nearly
81 exclusively from the myeloid lineage (CD11b⁺) (Extended Data Figure 2d and 3a). Lung
82 neutrophils are widely reported to enhance metastatic growth of cancer cells^{5,6}, and were
83 indeed detected within the Cherry-niche (Extended Data Figure 3b). We isolated Cherry-niche
84 neutrophils (Ly6G⁺) and compared their proteome to unlabelled neutrophils from the same
85 lungs (Figure 2a). We found the sub-pool of niche neutrophils to have distinct features, with
86 an increase in translational and oxidative phosphorylation activity (Figure 2b, Extended Data
87 Figure 3c, d and Supplementary File 1). Higher levels of intracellular ROS in Cherry-niche
88 neutrophils confirmed the increase in respiratory activity (Extended Data Figure 3e, f). To
89 validate the functional relevance of specific niche cells identified using the labelling tool for
90 cancer growth, we employed a co-culture system mimicking complex tissue-like cell-cell
91 interactions whereby primary cells are seeded on a three-dimensional (3D) scaffold (Alvetex).
92 When monitoring the growth of primary cancer cells isolated from the actin-GFP Mouse
93 Mammary Tumour Virus (MMTV) Polyoma virus Middle T antigen (PyMT) breast tumour
94 model, we found lung neutrophils to boost cancer cell growth in a ROS dependent manner
95 (Figure 2c-e and Extended Data Figure 3g, h). Collectively, these data highlight the potential
96 of Cherry-niche to detect *in vivo* changes spatially restricted to the cancer metastatic
97 environment.

98 Cherry-niche labelling during different stages of metastatic progression can additionally
99 provide spatio-temporal information. To gain unbiased insights into the niche signals, we
100 generated the gene expression profile of non-immune (CD45-ve) Cherry-niche cells at the
101 time point directly preceding micro-metastases as well as at an advanced metastatic stage
102 (Figure 2f, g). The majority of alterations were detected at the early stage, but additional
103 changes subsequently discriminated the niche of macro-metastases (Figure 2h and Extended
104 Data Figure 4a, b), confirming the evolution of the metastatic environment over time.

105 MetaCore dataset enrichment highlighted changes in pathways related to proliferation,
106 inflammation and tissue remodelling (Extended Data Figure 4c). We next focused on the
107 upregulated (>2) genes encoding for soluble factors in the niche versus the unlabelled cells
108 from the same lungs at both time points (Figure 2i). Again, as validation of the ability of our
109 labelling system to faithfully capture the *in vivo* niche, we could find many of previously
110 reported tumour promoting factors (Figure 2i)⁷⁻¹⁴. We also found Wnt1 induced protein
111 (Wisp1), previously suggested to act as oncogene in breast cancer¹⁵, to be an abundant niche

112 factor (Figure 2i). Indeed, upregulation of Wisp1 in both cancer and niche cells was detected
113 and its pro-metastatic activity was confirmed by exogenous inhibition *in vivo* (Figure 2j and
114 Extended Data Figure 5).

115 We next probed for the presence of previously uncharacterized niche cells, which are difficult
116 to resolve by standard techniques due to a lower frequency. Interestingly, we found pathways
117 associated with lung epithelial cells in the metastatic niche signature (Figure 2k). Micro-
118 metastases grow embedded within the alveolar compartment of the lung, and alveolar type II
119 cells (AT2) expressing Surfactant protein C (SP-C) were found in the metastatic environment
120 (Figure 3a). Using the epithelial cell adhesion molecule (Epcam) marker, we found Cherry-
121 niche epithelial cells predominantly as low/mid-Epcam epithelial cells, showing higher
122 proliferative activity (Figure 3b-d). Intriguingly, at the metastatic borders of human breast
123 cancer lung metastases we found the presence of alveolar cell clusters with increased
124 proliferative activity, suggesting that a lung parenchyma response to metastatic growth may
125 occur in both human and mouse (Extended Data Figure 6). Cancer cells profit from this
126 response, as freshly isolated Epcam⁺ cells from naïve lungs supported the growth of MMTV-
127 PyMT/GFP⁺ tumour cells in our 3D scaffold co-culture system (Figure 3e-g). Furthermore, in
128 line with previous data, the presence of both lung neutrophils and epithelial cells further
129 enhanced tumour growth (Extended Data Figure 7a-d).

130 We then focused on characterization of the perturbed lung epithelial cells in the niche. Firstly,
131 despite metastases growing within the alveolar region, we found a reduction in expression of
132 alveolar lineage markers in Cherry-niche epithelial cells (Figure 3a and 3h). To contextualize
133 their presence among the other niche cellular components, we performed single cell RNA
134 sequencing of CD45^{-ve} cells. tSNE analysis of Cherry-niche cells identified the presence of a
135 large stromal cluster, where different cancer associated fibroblasts (CAFs) subsets¹⁶ can be
136 identified (Figure 3i and Extended Data Figure 8). Notably, specifically in the niche, Epcam
137 expressing cells are distributed in two clusters distinguished by the expression of E-Cadherin
138 (Cdh1) (Fig 3i, j). We found that only niche Epcam⁺Cdh1⁺ cells share the expression of alveolar
139 genes¹⁷ with unlabelled lung Epcam⁺ cells (Fig 3k). Conversely, niche Epcam⁺Cdh1⁻ cells
140 express the Sca1 (Ly6a) and Tm4sf1 progenitor markers¹⁸⁻²⁰ (Fig 3k). The enrichment of
141 Epcam⁺Sca1⁺ cells was confirmed by FACS in the lung Cherry-niche of different metastatic
142 cell types (Figure 3l and Extended Data Figure 9a-c). Similarly, the presence of epithelial cells
143 expressing another lung progenitor marker, integrin β 4 (CD104)²¹, was increased in the niche
144 as well as in *ex vivo* co-cultures (Figure 3e and Extended Data Figure 9d-i).

145 Parenchymal cells have been previously described to trigger a tissue-wide inflammatory
146 response to systemic primary tumour signals, thereby increasing susceptibility to
147 metastasis^{22,23}. Conversely, here we provide evidence of a direct local parenchymal response

148 to invading cancer cells, whereby tissue epithelial cells become part of the metastatic
149 environment. Thus, we define them as cancer associated parenchymal cells (CAPs).
150 To functionally characterize CAP cells, we tested their lineage differentiation potential *ex vivo*
151 using a 3D Matrigel-based organoid co-culture system¹⁹ (Figure 4a). Unlabelled resident lung
152 Epcam⁺ cells largely contain alveolar cells, as previously shown¹⁹, and formed mainly alveolar
153 organoids in co-culture with CD31⁺ cells (Figure 4b-d). Strikingly, Cherry-niche Epcam⁺ cells
154 favoured the bronchiolar lineage and showed a remarkable capacity to generate multilineage
155 bronchioalveolar organoids (Figure 4b-d). However, there were no visible signs of Cherry
156 labelling in bronchial lineages *in vivo* in micro-metastasis (Extended Data Figure 10a). CAPs
157 also retained high self-renewal capacity over multiple passages (Figure 4e).
158 Next, we tested whether tumour cells could directly induce CAPs phenotype. Epcam⁺ cells
159 from either unlabelled distal micro-metastatic lungs or naïve lungs were co-cultured with
160 metastatic cells, generating a higher proportion of bronchiolar and bronchioalveolar organoids
161 (Figure 4f-h and Extended Data Figure 10b, c). Similar alterations were induced when co-
162 cultured with mouse lung fibroblasts (MLg) (Extended Data Figure 10b, c).
163 Certainly, lung Epcam⁺ cells are predominantly alveolar, but they contain other epithelial
164 progenitors that could be enriched by cancer cells to generate an increased plasticity^{19,24}.
165 Therefore, we performed organoid cultures using lineage-labelled AT2 cells (Sftpc-lineage).
166 Remarkably, AT2 lineaged cells, which show no *ex vivo* plasticity in co-culture with CD31⁺
167 cells, when exposed to cancer cells generated a remarkable amount of multilineage
168 bronchioalveolar organoids, supporting the idea of a reprogramming activity of cancer cell-
169 derived factors in this *ex vivo* assay (Figure 4i ,j). Importantly, metastases growing *in vivo* in
170 Sftpc-lineage mice demonstrated the alveolar origin of the epithelial cells in the niche (Figure
171 4k). Conversely, despite the potential of cancer cells to modulate the organoid formation ability
172 of lineage-labelled club cells (Scgb1a1-lineage), only rare single Scgb1a1-lineage cells were
173 found in proximity to lung metastases (Extended Data Figure 10d, e).
174 In summary, this study proposes a novel labelling system that enables cellular resolution of
175 the metastatic microenvironment. We provide examples of its potential to characterise host
176 tissue cell perturbations which are spatially restricted to regions surrounding cancer cells.
177 Remarkably, we report the presence of lung epithelial cells (CAPs) within the metastatic niche
178 showing striking tissue stem cell-like features, multilineage differentiation potential and
179 increased self-renewal activity. Taken together, these results show the power of Cherry-niche
180 to identify, isolate and functionally test tissue cells in the metastatic niche with unprecedented
181 spatial resolution.
182
183

184 ACKNOWLEDGMENTS

185 We thank E. Sahai, P. Scaffidi (The Francis Crick Institute, London) and V. Sanz-Moreno
186 (Barts Cancer Institute, London) for scientific discussions, critical reading of the manuscript
187 and sharing cell lines and mouse strains. We thank M. Izquierdo (CSIC, Madrid) for sharing
188 the CD63-GFP plasmid. We are grateful to E. Nye from the Experimental Histopathology Unit
189 and J. Bee from the Biological Resources Unit at the Francis Crick Institute for technical
190 support with mice and mouse tissues. We are also grateful to Robert Goldstone and Amelia
191 Edwards from the Advanced Sequencing Facility at the Francis Crick Institute for technical
192 support. We thank Miriam Llorian-Sopena from the Bioinformatics & Biostatistics Unit at the
193 Francis Crick Institute for helping with the RNA sequencing analysis. We also thank the Flow
194 Cytometry Unit at the Francis Crick Institute, particularly S. Purewal and J. Cerveira, for
195 invaluable technical help, and Cell Services Unit at the Francis Crick Institute. We are also
196 grateful to Irina Pshenichnaya, Peter Humphreys, Simon McCallum and Cambridge Stem Cell
197 Institute core facilities for technical assistance. This work was supported by the Francis Crick
198 Institute which receives its core funding from Cancer Research UK (FC001112), the UK
199 Medical Research Council (FC001112), and the Wellcome Trust (FC001112) and the
200 European Research Council grant (ERC CoG-H2020-725492); and by the Wellcome Trust –
201 MRC Stem Cell Institute which receives funding from the Sir Henry Dale Fellowship from
202 Wellcome and the Royal Society (107633/Z/15/Z) and the European Research Council
203 Starting Grant (679411).

204

205 AUTHOR CONTRIBUTIONS

206 L.O. designed and performed most of the experiments, analysed and interpreted the data and
207 contributed to the manuscript preparation. E.N. assisted with data collection, performed all the
208 3D-scaffold co-culture experiments, the *in vivo* Wisp1 experiments, the scRNA sequencing,
209 interpreted and analysed the data and contributed to the manuscript preparation. I.K.
210 performed the qPCR analysis, some of the tissue IF staining and analysed the data. A.M. and
211 J.H.L. performed some of the tissue IF staining, lung organoid experiments, interpreted and
212 analysed the data. V.B. performed some of the tissue IF staining. P.C. and S. H. performed
213 bioinformatics analysis. I.H., J.K. and A.O. performed the proteomic and analysed the data.
214 E.G.G. helped with the collection of Ly6G⁺ cells for proteomics. G.M. performed the 3D-
215 scaffold co-culture to analyse CD104⁺ cells. A.W. and L.C. performed the electron microscopy
216 experiments. E. H. and V. S. provided human samples. L.O., E.N., I.K., V.B. and J.H.L.,
217 critically reviewed the manuscript. J.H.L., supervised the lung organoid experiments. I.M.
218 designed and supervised the study, interpreted the data and wrote the manuscript.

219

220 **Competing interests**

221 The authors declare no competing financial interests.

222

223 **Materials & Correspondence**

224 Correspondence to Ilaria Malanchi and Joo-Hyeon Lee.

225

226 **Supplementary material files**

- 227 1. **Supplementary file 1:** entire list of differentially detected proteins (AVG Log2 Ratio)
228 in Cherry-niche versus unlabelled Ly6G⁺ neutrophils. Differences were considered
229 when changes were >0.58 and <-0.58.
- 230 2. **Supplementary file 2:** upregulated genes (>2 fold) in non-immune-Cherry-niche
231 compared to unlabelled lung tissue at both 5 and 10 days post cancer cells seeding.
- 232 3. **Supplementary file 3:** FACS gating strategy examples.

233


234 References

- 235 1. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and
236 metastasis. *Nature Medicine* **19**, 1423–1437 (2013).
- 237 2. Barash, S., Wang, W. & Shi, Y. Human secretory signal peptide description by hidden Markov
238 model and generation of a strong artificial signal peptide for secreted protein expression.
239 *Biochemical and Biophysical Research Communications* **294**, 835–842 (2002).
- 240 3. Flinterman, M. *et al.* Delivery of Therapeutic Proteins as Secretable TAT Fusion Products. *Mol*
241 *Ther* **17**, 334–342 (2009).
- 242 4. Shaner, N. C., Steinbach, P. A. & Tsien, R. Y. A guide to choosing fluorescent proteins. *Nat*
243 *Meth* **2**, 905–909 (2005).
- 244 5. Wculek, S. K. & Malanchi, I. Neutrophils support lung colonization of metastasis-initiating
245 breast cancer cells. *Nature* **17**, 413–417 (2015).
- 246 6. Coffelt, S. B., Wellenstein, M. D. & de Visser, K. E. Neutrophils in cancer: neutral no more.
247 *Nature review cancer* **16**, 431–446 (2016).
- 248 7. Kessenbrock, K., Plaks, V. & Werb, Z. Matrix Metalloproteinases: Regulators of the Tumor
249 Microenvironment. *Cell* **141**, 52–67 (2010).
- 250 8. Kowanetz, M. *et al.* Granulocyte-colony stimulating factor promotes lung metastasis through
251 mobilization of Ly6G+Ly6C+ granulocytes. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 21248–21255
252 (2010).
- 253 9. Qian, B.-Z. *et al.* CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.
254 *Nature review cancer* **475**, 222–225 (2011).
- 255 10. Acharyya, S. *et al.* A CXCL1 Paracrine Network Links Cancer Chemoresistance and
256 Metastasis. *Cell* **150**, 165–178 (2012).
- 257 11. Oskarsson, T. *et al.* Breast cancer cells produce tenascin C as a metastatic niche component
258 to colonize the lungs. *Nature Medicine* **17**, 867–874 (2011).
- 259 12. Erez, N. Opening LOX to metastasis. *Nature* **522**, 41–42 (2015).
- 260 13. Onnis, B., Fer, N., Rapisarda, A., Perez, V. S. & Melillo, G. Autocrine production of IL-11
261 mediates tumorigenicity in hypoxic cancer cells. *J. Clin. Invest.* **123**, 1615–1629 (2013).
- 262 14. Malanchi, I. *et al.* Interactions between cancer stem cells and their niche govern metastatic
263 colonization. *Nature* **481**, 85–89 (2011).
- 264 15. Su, F., Overholtzer, M., Besser, D. & Levine, A. J. WISP-1 attenuates p53-mediated apoptosis
265 in response to DNA damage through activation of the Akt kinase. *Genes Dev.* **16**, 46–57
266 (2002).
- 267 16. Costa, A. *et al.* Fibroblast Heterogeneity and Immunosuppressive Environment in Human
268 Breast Cancer. *CCELL* **33**, 463–479.e10 (2018).
- 269 17. Treutlein, B. *et al.* Reconstructing lineage hierarchies of the distal lung epithelium using single-
270 cell RNA-seq. *Nature* **509**, 371–375 (2014).
- 271 18. Kim, C. F. B. *et al.* Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung
272 Cancer. *Cell* **121**, 823–835 (2005).
- 273 19. Lee, J.-H. *et al.* Lung Stem Cell Differentiation in Mice Directed by Endothelial Cells via a
274 BMP4-NFATc1-Thrombospondin-1 Axis. *Cell* **156**, 440–455 (2014).
- 275 20. Zacharias, W. J. *et al.* Regeneration of the lung alveolus by an evolutionarily conserved
276 epithelial progenitor. *Nature* **555**, 251–255 (2018).
- 277 21. Chapman, H. A. *et al.* Integrin $\alpha 6 \beta 4$ identifies an adult distal lung epithelial population with
278 regenerative potential in mice. *J. Clin. Invest.* **121**, 2855–2862 (2011).
- 279 22. Liu, Y. *et al.* Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by
280 Activating Alveolar Epithelial TLR3 to Recruit Neutrophils. *CCELL* **30**, 243–256 (2016).
- 281 23. Lee, J. W. *et al.* Hepatocytes direct the formation of a pro-metastatic niche in the liver. *Nature*
282 **567**, 249–252 (2019).
- 283 24. McQualter, J. L., Yuen, K., Williams, B. & Bertoncello, I. Evidence of an epithelial
284 stem/progenitor cell hierarchy in the adult mouse lung. *Proc Natl Acad Sci USA* **107**, 1414–
285 1419 (2010).
- 286

287 **Figures and Legends**

288

289 **Figure 1**



290

291 **Figure 1 - Cherry-niche labelling strategy.**

292 **a**, Labelling design. **b-d**, FACS plots of (b) non-labelled (recipient) 4T1 cells alone or (c) co-
293 cultured with Labelling-4T1 and (d) fluorescence image from co-culture (Scale bar 10µm). **e-**
294 **g**, *In vivo* labelling: (e) schematic experimental design; (f) representative immuno-
295 fluorescence (IF) images of Labelling-4T1 metastasis: cancer cells GFP (green) and Cherry
296 (red), niche cells (Cherry only). DAPI (blue). Scale bars: main 20µm, inset 10µm; (g)
297 representative FACS plot of a dissociated metastatic lung.

298

299

300

301

302


303

304

305

306

307 **Figure 2**




308 **Figure 2 - Cherry-niche allows detection of niche cells and identification of niche**
 309 **factors.**

310 **a,b**, Proteomic analysis of Ly6G⁺ FACS-sorted cells: (a) all differentially detected proteins and
 311 (b) heatmap of oxidative phosphorylation associated proteins. **c-e**, 3D co-culture with MMTV-
 312 PyMT-GFP⁺ cancer cells, Ly6G⁺ MACS-sorted cells with or without the ROS inhibitor TEMPO:

313 (c) co-culture scheme; (d) representative pictures at day 6 (scale bar 400 μ m); (e) GFP signal
314 quantification. Data normalised to cancer cell growth. Data show three independent
315 experiments (dots), each performed with 3 to 10 technical replicates. Data are represented as
316 mean \pm SEM. **f**, Schematic experimental design for RNA-seq. **g**, Schematic of metastatic
317 progression using 4T1 cells. **h**, Principle Component Analysis (PCA) diagram of CD45⁻Ter119⁻
318 cell signatures. **i**, Venn diagram of differentially expressed genes in Cherry-niche from RNA-
319 seq and selected factors common at early and late stages. **j**, Anti-Wisp1 blocking antibody
320 treatment *in vivo* (n=10 from two independent experiments; each dot represents one animal
321 on a Tukey plot). A third experiment with higher overall metastatic frequency is quantified in
322 Extended Data Figure 5d, e. **k**, GSEA correlation from RNA-seq data. Statistical analysis by
323 Two-way ANOVA (e) and unpaired two-tailed t-test with Welch's correction (j).

324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347



349 **Figure 3 - Cherry-niche reveals lung epithelial cells with progenitor phenotype in the**
 350 **metastatic niche.**

351 **a**, Representative IF image of lung tissue showing: mCherry-labelled micro-metastasis (red),
 352 Surfactant protein C (SP-C) (white) and DAPI (blue). Scale bars: main 100µm, inset 10µm
 353 (white arrows show mCherry labelled SP-C+ cells). **b**, Epcam+ cell frequency on Lin- (CD45-
 354 CD31-Ter119-) cells in distal lung (Ch-) and Cherry-niche (Ch+) by FACS (n=13). **c**,
 355 Representative FACS plots from (b). **d**, Scatter plot of Epcam+ cell proliferation tested by Ki67
 356 staining on FACS-sorted cells (n=6 from independent sorts). **e-g**, MMTV-PyMT-GFP+ cancer

357 cell growth in 3D co-culture with MACS-sorted Epcam⁺ cells: (e) co-culture scheme, (f)
358 representative pictures at day 6 (scale bar 400 μ m), (g) GFP signal quantification; 3-4 technical
359 replicates per experiment; four independent sorts (dots); data normalised to cancer cell
360 growth. **h**, qRT-PCR analysis of Epcam⁺ FACS-sorted cells (three samples from independent
361 sorts, all technical replicates shown). Data normalised to Ch⁻ Lung Epcam cells. **i, j**, tSNE
362 plots of CD45⁻ cells from (i) Cherry-niche or (j) distal lung after scRNA-seq analysis. **k**,
363 Heatmap showing differences in gene expression of niche Epcam⁺ cells (Cdh1⁺ or Cdh1⁻);
364 genes hierarchically clustered in rows and cells in columns; inset table shows established
365 lineage markers (**bold**) and putative alveolar markers¹⁷ (*). **l**, Epcam⁺Sca1⁺ cell frequency on
366 Lin⁻ (CD45⁻CD31⁻Ter119⁻) cells by FACS (n=13). Statistical analysis was performed by
367 Wilcoxon matched-pairs signed rank test (l), paired two-tailed t-test (b, d), one sample t-test
368 (g) with a Benjamini-Hochberg correction (h). Data represented as mean \pm SEM.

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384


385

386

387

388

389 **Figure 4**



390
 391 **Figure 4 - Cancer associated parenchymal cells (CAPs) show multilineage**
 392 **differentiation potential.**

393 **a-e**, Lung organoids: (a) co-culture scheme; (b) representative bright-field images (scale bar
 394 100µm); (c) representative IF of organoid sections stained with the indicated markers (scale
 395 bar 50µm); (d) quantification; (e) organoid formation efficiency over passages. **f-h**, Lung
 396 organoids with or without Labelling-4T1: (f) co-culture scheme, (h) quantification and (g)
 397 representative bright-field pictures (scale bar 100µm). **i, j**, Lung organoids with Sftpc-CreERT2
 398 lineage cells with or without 4T1-GFP: (i) quantification and (j) representative bright-field
 399 pictures, scale bar 150µm. **k**, Representative staining of lineage cells in metastatic lungs from

400 Sftpc-CreERT2 mice injected with cancer cells, either E0771 (scale bar 50 μ m) or MMTV-
401 PyMT (scale bar 100 μ m). Data presented are the mean of two independent sorts with triplicate
402 wells \pm SD (d, e, h) and sorted AT2-lineaged cells co-cultured in triplicate wells \pm SD (i).
403 Statistical analysis was performed by two-tailed t-test (d, e, h) and one sample t-test (i).

404

405

406

407

408

409

410

411


412

413

414

415 Extended Data Figures and Legends

416 Extended Data Figure 1



417 **Extended data Figure 1 - Cherry-niche *in vitro***

418 **a**, sLP-mCherry design. **b**, Fluorescence images of Labelling-4T1 cells post-thawing. Scale
419 bar 10 μ m. **c**, Representative FACS plot of Labelling-4T1 cells. **d**, *In vitro* cultures of the
420 indicated cell types with Labelling-4T1 cell conditioned media (LCM): culture scheme and
421 representative fluorescence images of HC11 (murine mammary epithelial cells) and hNLF
422 (human normal lung fibroblasts) with LCM (scale bar 10 μ m). **e**, FACS plots of 4T1, HC11,
423 RAW264.7 (murine macrophages), hNLF, murine breast Carcinoma Associated Fibroblasts
424 (CAF) cultured with LCM. **f**, FACS analysis of 293T cells cultured with LCM, at different time-
425 points after LCM removal (black dots); white dots show the theoretical decrease considering
426 the cell proliferation rate only (the amount of 293T cells mCherry labelled after 24h incubation
427 with LCM was set to 100%). **g**, Representative fluorescence image of 4T1-CD63GFP cells
428 cultured with LCM. Scale bars: main 5 μ m, inset 1 μ m. **h**, Representative Correlative Light and
429 Electron Microscopy (CLEM) of Labelling-4T1 cells re-up-taking sLP-mCherry: upper-left
430 panel shows bright-field image overlaid mCherry IF (~700nm optical section); lower-left panel
431 shows EM of same cell (~70nm section thickness); large central panel shows best
432 approximation of IF/bright-field/EM overlay (scale bar 5 μ m); right panels show EM insets from
433 indicated areas in the large central panel (black arrows point at vesicular structures containing
434 the mCherry, scale bar 1 μ m). **i**, **j**, Analysis of *in vitro* labelling potential of soluble fraction and
435 extracellular vesicles (EVs) isolated from LCM by FACS: (i) schematic representation of LCM
436 fractionation; (j) HC11 cells cultured with either LCM, soluble fraction after EVs depletion
437 (soluble) or purified EVs. **k**, ImageStream analysis of Cherry⁺ EVs in LCM (16% of total EVs
438 are Cherry⁺).

439

440

441

442

443

444

445

446

447


448

449

450

451


452 **Extended Data Figure 2**



453 **Extended data Figure 2 - Cherry-niche *in vivo*.**

454 **a, b**, Distance of labelled cells within metastases: (a) representative fluorescence images
 455 (lines measure the maximum distance of labelled cells (mCherry) from Labelling-4T1 cells
 456 (mCherry/GFP); scale bar 50µm); (b) quantification of labelling distance in micro-metastases
 457 and macro-metastases (n=11 micro-metastases and n=4 macro-metastases). **c**, Correlation
 458 between the percentage of mCherry labelled niche cells and the percentage of cancer cells in
 459 metastatic lungs analysed by FACS: (left) only low number of cancer cells (right) all cancer
 460 cell frequencies. Statistical analysis by linear regression. **d-f**, CD45⁺ cell frequency on live
 461 cells in distal lung, Cherry-niche and naïve lungs (collected from mice which were not injected)
 462 by FACS: (d) Balb/c mice injected with Labelling-4T1 cells (n=5 per group); (e) Balb/c mice
 463 injected with Labelling-HC11 cells (n=4); (f) Rag1ko mice injected with Labelling-4T1 cells
 464 (n=10). Statistical analysis by paired two-tailed t-test. Data are represented as mean ±SEM.

465 **Extended Data Figure 3**



466

467 **Extended data Figure 3 - Cherry-niche neutrophils increase ROS production.**

468 **a, b,** (a) CD11b⁺ and (b) Ly6G⁺ cell frequencies on live cells in distal lung and Cherry-niche by

469 FACS (n=9 per group). **c,** Enriched processes by MetaCore analysis and GSEA on Cherry-

470 niche neutrophils dominant proteins using WebGestalt

471 (<http://www.webgestalt.org/option.php>). **d,** PCA of proteins found in unlabelled or Cherry-

472 niche neutrophils: small circles represent proteomic data from each independent sorts and

473 large circles represent the average of the triplicates. **e,** Representative FACS plot and **f,**

474 scatter plot of intrinsic ROS in Ly6G cells (n=6). **g,** GFP signal quantification of 3D co-culture


475 with MMTV-PyMT-GFP⁺ cancer cells, Ly6G⁺ MACS-sorted cells from either naïve or

476 metastatic lungs with or without the ROS inhibitor TEMPO. Data is normalised to cancer cell

477 growth. Each dot represents an independent experiment performed in triplicate. **h**,
 478 Representative cancer cell growth on the scaffold: integrated density of the GFP signal
 479 measure on the scaffold using ImageJ and the corresponding fluorescent image of GFP+
 480 cancer cell growth (scale bar 400µm). Statistical analysis by paired two-tailed t-test (a, b, f)
 481 and Two-way ANOVA (g). Data represented as mean ±SEM.

482

483 **Extended Data Figure 4**




484 **Extended data Figure 4 - RNA sequencing of non-immune Cherry-niche cells.**

485 **a, b**, GSEA on Cherry-niche upregulated genes: (a) percentage of correlating processes
 486 related to the indicated activity and (b) specific signalling pathways (indicated by the * in (a)
 487 either at early or late time point). **c**, MetaCore analysis on genes differentially expressed in
 488 Cherry-niche versus unlabelled lung cells by RNA-seq.

489

490 **Extended data Figure 5**




491 **Extended data Figure 5 - Wisp1 supports metastatic growth.**

492 **a, b**, Representative IF images of lung metastatic tissues stained with GFP (green) to detect
 493 Labelling-4T1 cells, WISP1 (red) and DAPI (blue) showing distal lung and metastatic areas,
 494 scale bar 50 μm; (b) a representative image showing the enrichment of Wisp1⁺ cells within
 495 lung metastasis including niche cells (white arrows); scale bar 50μm. **c-e**, Anti-WISP1 blocking
 496 antibody treatment *in vivo*: (c) experimental design (IT, intratracheal injection; IP,

497 intraperitoneal injection); (d) metastatic outcome measured as the percentage of lung area
 498 covered by metastases (quantification was performed on two lung levels 100µm apart); (e)
 499 representative H&E pictures (black arrows show metastatic foci), scale bar 500µm.

500

501 **Extended Data Figure 6**



502 **Extended data Figure 6 – Lung pneumocytes react to cancer cells in human breast**
 503 **pulmonary metastases.**

504 **a-c**, Histology on human breast tumour lung metastases sections: (a) representative image of
 505 distal lung (scale bar 100µm); (b) image from the tumour-lung interface showing TTF1 cluster
 506 (scale bar 50µm); (c) representative histology images from metastatic border (scale bar
 507 100µm). **d-f**, Alveolar cell proliferation in human breast tumour lung metastases analysed by


508 IF: representative pictures from (d) distal lung and (e) metastatic border showing TTF1 (red),
 509 Ki67 (green) and DAPI (blue), scale bars: main 100 μ m, inset 50 μ m; (f) quantification.

510

511

512

513 **Extended Data Figure 7**



514 **Extended data Figure 7 - Epithelial cells support cancer cell growth *ex vivo*.**


515 **a**, MMTV-PyMT-GFP⁺ cancer cell proliferation in 2D co-culture with MACS-sorted Epcam⁺ and
 516 Ly6G⁺ cells stained with EdU and analysed by FACS (n=3 independent experiments). Data
 517 normalised to cancer cell proliferation. **b-d**, 3D co-culture of MMTV-PyMT-GFP⁺ cancer cell
 518 with MACS-sorted Epcam⁺ and Ly6G⁺ cells: (b) co-culture scheme; (c) representative pictures
 519 at day 4, scale bar 400 μ m; (d) GFP signal quantification. Data normalised to cancer cell growth
 520 (Dots represent independent sorting experiments performed with 3-4 technical replicates).
 521 Statistical analysis by one sample t-test (a) and Two-way ANOVA (d). Data are represented
 522 as mean \pm SEM.

523

524

525

526 **Extended Data Figure 8**



527 **Extended data Figure 8 - scRNA-seq analysis reveals different sub-pools of stromal**
 528 **cells in the niche.**

529 **a**, tSNE plots of CD45⁻ cells isolated from distal lung or Cherry-niche after scRNA-seq
 530 analysis: the CAFs are coloured based on the expression levels of the indicated genes. **b**,
 531 tSNE plots split up from the niche plot in (a), where each plot shows in red the cells expressing
 532 the indicated stromal marker. **c**, MetaCore pathway enrichment analysis using the list of genes
 533 detected in at least 50% of the indicated marker defined cells.

534


535

536

537

538

539 **Extended Data Figure 9**




540 **Extended data Figure 9 - Cherry-niche epithelial cells are enriched for stem cell**
 541 **markers.**

542 **a**, Representative FACS plots showing Lin⁻ (CD45⁻CD31⁻Ter119⁻) cells in distal lung and
 543 Cherry-niche from Labelling-4T1 injected mice (quantification in Fig.3I). **b**, **c**, Scatter plots
 544 showing FACS quantification of Epcam⁺Sca1⁺ cell frequency on Lin⁻ (CD45⁻CD31⁻Ter119⁻)
 545 cells in distal lung and Cherry-niche with (b) Labelling-RENCA (n=5) and (c) Labelling-CT26
 546 (n=4). **d-f**, (d) Scatter plot of CD49f⁺CD104⁺ cell frequency on Lin⁻ (CD45⁻CD31⁻Ter119⁻) cells
 547 in distal lung and Cherry-niche by FACS (n=5); (e) representative FACS plots; (f)
 548 representative IF image of FACS-sorted Cherry-niche CD49f⁺CD104⁺ cells using E-cadherin
 549 (green) and DAPI (blue); scale bar 20µm. **g-i**, 3D co-culture of MMTV-PyMT-GFP⁺ cancer cell
 550 with MACS-sorted Epcam⁺ cells: (g) quantification of integrin β4 (CD104) expression on
 551 Epcam⁺ cells; (h) number of CD104⁺ cells proximal to cancer cells (n=4 from three
 552 independent sorts); (i) representative IF image from the co-culture stained with CD104 (red);

553 GFP⁺ cancer cells (green) and DAPI (blue); scale bar 20 μ m. Statistical analysis by paired two-
 554 tailed t-test (b-d, g). Data represented as mean \pm SEM.

555

556 **Extended Data Figure 10**



557

558 **Extended data Figure 10 - Cancer cells change lung epithelial cell lineage commitment**
559 ***ex-vivo*.**
560 **a**, Representative IF images of lung metastatic sections co-stained with airway markers, either
561 (a) Scgb1a1 (white) or (b) Sox2 (white), Cherry (red) and DAPI (blue); scale bar 100 μ m. **b, c**,
562 Lung organoids with Epcam⁺ FACS-sorted cells in co-culture with either lung stromal CD31⁺
563 cells or MLg fibroblasts alone or in presence 4T1-GFP cells from metastatic lungs in the lower
564 chamber: (b) quantification and (c) representative bright-field images of organoids, scale bar
565 150 μ m. **d**, Lung organoids with Scgb1a1-CreERT2 lineage cells with or without 4T1-GFP:
566 quantification and representative bright-field pictures, scale bar 150 μ m. **e**, Representative
567 staining of lineage cells in metastatic lungs from Scgb1a1-CreERT2 mice injected with MMTV-
568 PyMT cancer cells. Scale bars: main 50 μ m, apart from the first 2 panels where is 200 μ m (inset
569 25 μ m). Sorted Epcam (b) or club-lineage cells (d) were co-cultured in triplicate wells \pm SD.
570 Statistical analysis was performed by two-tailed t-test.
571
572

573 **Methods**

574

575 **Statistical Analysis**

576 Statistical analyses were performed using Prism software (version 7.0c, GraphPad Software,
577 USA) with the exception of the qRTPCR data, for which R was used. P values were obtained
578 from two-tailed Student t-tests with paired or unpaired adjustment. When needed, unpaired t-
579 test were adjusted using Welch's correction for unequal variance. In one instance (Fig. 3I)
580 data in one of the groups did not pass D'Agostino & Pearson normality test, therefore a
581 Wilcoxon matched-pairs signed rank test was performed. For qRTPCR data, single-sample
582 tests with a Benjamini-Hochberg correction to account for multiple testing were performed.
583 Single-sample tests were also used for comparisons of co-cultured cancer cell growth on
584 scaffolds to the normalized value of cancer cells alone. For comparisons between two scaffold
585 conditions of growth over time or to perform multiple analysis between experimental groups,
586 Two-way ANOVA was used.

587

588 **Data availability**

589 The single cell RNA sequencing datasets are being deposited in the Gene Expression
590 Omnibus (GEO, NCBI) repository. RNA sequencing datasets are deposited with GEO
591 (GSE117930) and the proteomic datasets in PRoteomics IDentifications (PRIDE) repository
592 (PXD010597). All data are available upon request during the review process.

593

594 **Mouse strains**

595 All mice used are available from Jackson Laboratory. MMTV-PyMT mice²⁵ on FVB and
596 C57BL/6 background, actin-GFP²⁶ mice and Rag1KO are on FVB background (gift from J.
597 Huelsken laboratory (EPFL, Lausanne, Switzerland)). *Sftpc-CreERT2*²⁷, *Rosa26R-YFP*²⁸
598 (*Sftpc-CreERT2;R26R-YFP*) are on a C57BL/6 background. Balb/cj mice and the above-
599 mentioned lines were bred and maintained under specific-pathogen-free conditions by The
600 Francis Crick Biological Research Facility and female mice were used between 6 to 10 weeks
601 of age. Breeding and all animal procedures were performed at the Francis Crick in accordance
602 with UK Home Office regulations under project license P83B37B3C.

603 For *ex-vivo* organoids lineage tracing experiments, *Scgb1a1-CreERT2*²⁹, *Sftpc-CreERT2*²⁷,
604 and *Rosa26R-fGFP*²⁹ (*Sftpc-CreERT2;R26R-fGFP* and *Scgb1a1-CreERT2;R26R-fGFP*) on a
605 C57BL/6 background were bred and maintained under specific-pathogen-free conditions at
606 the Gurdon Institute of University of Cambridge in accordance with UK Home Office project
607 licence PC7F8AE82.

608

609 **Tamoxifen administration**

610 Tamoxifen (Merck Sigma-Aldrich, Germany) was dissolved in Mazola corn oil (Merck Sigma-
611 Aldrich, Germany) in a 20mg/ml stock solution. Two doses of tamoxifen (0.2mg/g body weight)
612 were given via oral gavage every other day and lung tissues were collected two days after
613 tamoxifen administration to isolate cells for lung organoids. For *in vivo* lineage tracing three
614 doses of tamoxifen (0.2mg/g body weight) were given via oral gavage over consecutive days
615 and mice were injected two weeks later.

616

617 **Cells**

618 MLg cells (murine normal lung fibroblasts) were purchased from ATCC (USA). CAF (cancer
619 associated fibroblasts) isolated from MMTV-PyMT tumours and human normal fibroblast
620 (hNLF) were a gift from E.Sahai. All other cell lines were provided by the Cell Services Unit of
621 The Francis Crick Institute. MMTV-PyMT cells were cultured on collagen solution coated
622 dishes in MEM medium (DMEM/F12 (ThermoFisher Scientific, USA) with 2% fetal bovine
623 serum (FBS; Labtech, UK), 100 U ml⁻¹ penicillin-streptomycin (ThermoFisher Scientific, USA),
624 20 ng ml⁻¹ EGF (ThermoFisher Scientific, USA) and 10 µg ml⁻¹ insulin (Merck Sigma-Aldrich,
625 Germany)). Collagen solution is made by 30 µg/mL PureCol collagen (Advanced Biomatrix,
626 USA), 0.1% bovine serum albumin (BSA), 20 mM HEPES in HBSS (ThermoFisher Scientific,
627 USA). HC11 cells were cultured in RPMI (ThermoFisher Scientific, USA) supplemented with
628 10% FBS, 100 U ml⁻¹ penicillin-streptomycin, 10 ng ml⁻¹ EGF (ThermoFisher Scientific, USA)
629 and 5 µg ml⁻¹ insulin. All other cell lines were cultured in DMEM (ThermoFisher Scientific, USA)
630 supplemented with 10% FBS and 100 U ml⁻¹ penicillin-streptomycin. All cells were cultured at
631 37°C and 5% CO₂.

632

633 **Human Samples**

634 Human pulmonary breast cancer metastases from independent patients were obtained from
635 the Grampian Biorepository, Aberdeen Royal Infirmary (REC approval: 16/NS/0055). Four
636 samples were stained by Immunohistochemistry and Immunofluorescence and epithelial cells
637 proliferation was quantified.

638

639 **Labelling system**

640 A soluble peptide (SP)² and a modified TAT peptide³ were cloned upstream of the mCherry
641 cDNA, under the control of a mouse PGK promoter (sLP-Cherry). The sLP-Cherry sequence
642 was cloned into a pRRL lentiviral backbone. 4T1, Renca, CT26 and HC11 cells were stably
643 infected with sLP-Cherry and pLentiGFP lentiviral particles and subsequently sorted to isolate
644 Cherry⁺GFP⁺ cells.

645

646 **Induction of experimental metastases**

647 For experimental metastases, 4T1 (1,000,000 cells), Renca (500,000 cells), CT26 (200,000
648 cells) were re-suspended in 100 µl PBS and tail-vein injected in Balb/cJ mice.

649

650 ***In vivo* lineage tracing experiments**

651 *Sftpc-CreERT2* and *Scgb1a1-CreERT2* mice on C57BL/6 background were tail-vein injected
652 either with 175,000 MMTV-PyMT C57BL/6 cells and lungs collected 4 weeks later or with
653 700,000 E0771 cells and lungs collected 12 days later.

654

655 **Tissue digestion for cell isolation or analysis**

656 Lung tissues were dissociated as previously described¹⁴. Briefly, lungs were removed at day
657 7 after tumour cell injection (unless otherwise specified), minced manually and then digested
658 for 30 min in a shaker at 37°C with a mixture of DNase I (Merck Sigma-Aldrich, Germany) and
659 Liberase TM and TH (Roche Diagnostics, Switzerland) in HBSS solution. Samples were then
660 washed, passed through a 100 µm filter and incubated in Red Blood Cell Lysis buffer (Miltenyi
661 Biotec, Germany) for 3-5 min at room temperature. After a wash with MACS buffer (0.5% BSA
662 and 250 mM EDTA in PBS), samples were passed through a 40 µm filter and a 20 µm strainer-
663 capped flow cytometry tube to generate a single cell suspension to use for flow cytometric
664 analysis or further purification.

665

666 **FACS analysis and cell sorting**

667 Prepared single-cell suspensions of mouse lung tissues and *in vitro* cell lines were incubated
668 with mouse FcR Blocking Reagent (Miltenyi Biotec, Germany) for 10 min at 4°C followed by
669 an incubation with a mix of pre-labelled antibodies (antibody information is provided in the
670 table below) for 30 min at 4°C. After two washes with MACS buffer, dead cells were stained
671 with 4',6-diamidino-2-phenylindole (DAPI). Flow cytometry analyses were carried out on a BD
672 LSR-Fortessa (BD Biosciences, USA) and FlowJo 10.4.2 (FlowJO, LCC 2006-2018, USA)
673 was used for further analysis. All cell-sorting experiments were carried out on a BD Influx cell
674 sorter (BD Biosciences, USA).

675

676 **Tissue digestion and FACS analysis in *ex-vivo* lineage tracing experiments**

677 Lung tissues were dissociated with a collagenase/dispase solution as previously described³⁰.
678 Briefly, after lungs were cleared by perfusion with cold PBS through the right ventricle, 2 mL
679 of dispase (50 U/ml, BD Biosciences, USA) was instilled into the lungs through the trachea
680 until the lungs inflated, followed by instillation of 1% low melting agarose (Bio-Rad
681 Laboratories, USA) through the trachea to prevent leakage of dispase. Each lobe was

682 dissected and minced into small pieces in a conical tube containing 3 ml of PBS, 60 μ L of
683 collagenase/dispase (Roche, Switzerland), and 7.5 μ L of 1% DNase I (Merck Sigma-Aldrich,
684 Germany) followed by rotating incubation for 45 min at 37°C. The cells were then filtered
685 sequentially through 100- and 40- μ m strainers and centrifuged at 1000rpm for 5 min at 4°C.
686 The cell pellet was resuspended in 1 ml of ACK lysis buffer (0.15 M NH₄Cl, 10mM KHCO₃,
687 0.1 mM EDTA) and lysed for 90 s at room temperature. 6 ml basic F12 media (ThermoFisher
688 Scientific, USA) was added and 500 μ l of FBS (Fisher Scientific, USA) was slowly added in
689 the bottom of tube. Cells were centrifuged at 1500 rpm for 5 min at 4°C. The cell pellet was
690 resuspended in PF10 buffer (PBS with 10% FBS) for further staining. The antibodies used
691 were as follows: CD45 (30-F11)-APC (BD Biosciences, USA), CD31 (MEC13.3)-APC (BD
692 Biosciences, USA), and EpCAM (G8.8)-PE-Cy7 (BioLegend, USA). MOFLO system
693 (Beckman Coulter, USA) was used for the sorting at Wellcome-MRC Stem Cell Institute Flow
694 Cytometry Facility.

695

696 **Lung organoid assay**

697 Lung organoid co-culture assays were previously reported³. Briefly, freshly sorted epithelial
698 cells (Epcam⁺CD45⁻CD31⁻Ter119⁻GFP⁻) from either the metastatic niche or the distal lung
699 were resuspended in 3D basic media (DMEM/F12, supplemented with 10% FBS,
700 penicillin/streptomycin, 1 mM HEPES, and insulin/transferrin/selenium (ITS) (Merck Sigma-
701 Aldrich, Germany), and mixed with MACS-sorted CD31⁺ lung stromal cells or MLg cells
702 followed by resuspension in growth factor-reduced (GFR) Matrigel (BD Biosciences, USA) at
703 a ratio of 1:1. 100 μ l of mixture was then placed in a 24-well transwell insert with a 0.4 μ m
704 pore (Corning, USA). 1-2.5 x10³ distal lung or niche epithelial cells and 25,000 CD31⁺ or MLg
705 cells were seeded in each insert. 500 μ l of 3D basic media was placed in the lower chamber
706 and media was changed every other day. In addition, freshly sorted lineage-labelled Scgb1a1⁺
707 club cells or Sftpc⁺ AT2 cells were resuspended in 3D basic media followed by mixing with
708 GFR matrigel retaining CD31⁺ stromal cells as described above. For co-culture of lung
709 epithelial cells with tumour cells, a mixture of 1-2.5 x10³ distal lung epithelial cells and 25,000
710 CD31⁺ cells in Matrigel was placed in the transwell insert, and 2,000 tumour cells FACS-sorted
711 from metastatic lungs were seeded in the lower chamber. Plates were scored for colony
712 number after 14 days. Colony-forming efficiency was calculated as number of colonies
713 formed/number of cells plated per well as a percentage. Quantification of distinct types of
714 differentiated colonies was performed by scoring the colonies expressing Sox2 or SP-C/Hopx
715 by IF staining from at least five step sections (20 μ m apart) per individual well. Bright-field
716 images were acquired after 14 days using an EVOS microscope (ThermoFisher Scientific,
717 USA).

718

719 **3D Cell culture**

720 Primary MMTV-PyMT actin-GFP cells were seeded at a density of 5,000 cells/well in a
721 collagen solution coated Alvetex Scaffold 96-well plate (ReproCELL, Europe). The following
722 day, Ly6G⁺ lung cells and/or Epcam⁺ lung epithelial cells were MACS sorted and seeded on
723 top of the cancer cells at a density of 50,000 cells per well. In selected experiments, wells
724 were supplemented with 4-Hydroxy-TEMPO (Merck Sigma-Aldrich, 200 μ M) or mouse anti-
725 Wisp1 (250 ng/mL, MAB1680, R&D, USA). The growth of GFP⁺ cells was monitored daily for
726 6 days using the SteREO Lumar.V12 stereomicroscope (Zeiss, Germany), and images were
727 quantified using ImageJ (NIH, USA). For quantification, the Li's Minimum Cross Entropy
728 thresholding algorithm was performed on the stacked images.

729 For the CD104 staining experiment, Epcam⁺ lung cells were harvested from mouse lung tissue
730 via MACS sorting and seeded at a density of 1,500,000 cells per well on collagen solution
731 coated Alvetex Scaffold 12-well inserts. After 48 h, MMTV-PyMT actin-GFP cells were seeded
732 on top of the Epcam⁺ cells at a density of 2,000 cells per scaffold insert.

733

734 **Immunofluorescence and immunohistochemistry**

735 Mouse lungs were fixed in 4% PFA in PBS for 24 h and embedded in paraffin blocks. 4 μ m
736 thick tissue sections were cut, deparaffinised and rehydrated using standard methods. After
737 heat-mediated antigen retrieval in citrate buffer (unless stated otherwise), sections were
738 blocked with a solution of 1% BSA, 10% Donkey serum in PBS.

739 ***mCherry and GFP staining.*** An overnight incubation at 4°C with goat anti-GFP and rabbit
740 anti-mCherry antibodies was followed by 1 h incubation at room temperature with anti-goat
741 AlexaFluor 488 and anti-rabbit AlexaFluor 555 (both secondary antibodies were purchased
742 from ThermoFisher Scientific (USA) and used at 1:400). Next, the slides were incubated with
743 Sudan Black B for 20 min and mounted with Vectashield Mounting Medium with DAPI (Vector
744 Laboratories, USA).

745 ***Lineage staining.*** An overnight incubation at 4°C with goat anti-GFP antibody was followed
746 by 45 min incubation at room temperature with secondary biotinylated-conjugated antibodies.
747 Next, the VECTASTAIN Elite ABC kit (Vector Laboratories, USA) was used according to the
748 manufacturer's instructions. The visualization of cell nuclei was performed with hematoxylin
749 and analysis employed the Nikon Eclipse 90i light microscope and NIS-elements software.

750 ***WISP1 staining.*** An overnight incubation at 4°C with goat anti-GFP and rabbit anti-mCherry
751 antibodies was followed by 30 min incubation at room temperature with anti-goat AlexaFluor
752 488 and anti-rabbit AlexaFluor 555 (both secondary antibodies were purchased from
753 ThermoFisher Scientific (USA) and used at 1:500). Next, the slides were incubated with Sudan
754 Black B for 20 minutes and mounted with Vectashield Mounting Medium with DAPI (Vector
755 Laboratories, USA).

756 **Ki67 staining.** Epcam⁺CD45⁻CD31⁻Ter119⁻GFP⁻ cells were sorted from lung suspensions,
757 plated on poly-lysine glass coverslips for 15 min at room temperature and fixed in 4% PFA in
758 PBS for 10 min. After fixation, cells were permeabilized with 0.1% Triton-X-100 in PBS for 5
759 min and incubated with a blocking solution (1% BSA, 10% goat serum, 0.3 M glycine, 0.1%
760 Tween in PBS) for 1 h at room temperature. Next, cells were incubated overnight with an anti-
761 mouse Ki67 antibody diluted in blocking solution followed by a 1 h incubation with a goat anti-
762 rabbit AlexaFluor 488 (1:500, ThermoFisher Scientific (USA)). Finally, cells were mounted with
763 Vectashield Mounting Medium with DAPI for imaging.

764 **E-cadherin staining.** CD49f⁺CD104⁺CD45⁻CD31⁻Ter119⁻GFP⁻ cells were sorted from lung
765 suspensions, cytopspun on glass slides and fixed in 4% PFA in PBS for 10 min. Next, cells
766 were permeabilized with 0.5% TritonX-100 for 30 min and incubated in blocking solution (4%
767 BSA, 0.05% Tween20 in PBS) for 45 min at room temperature. Then, cells were incubated
768 with a rat anti-E-cadherin antibody in blocking solution overnight at 4°C followed by an
769 incubation with a goat anti-rat AlexaFluor 647 (1:500, ThermoFisher Scientific (USA)). Finally,
770 cells were mounted with Vectashield Mounting Medium with DAPI for imaging.

771 **CD104 staining.** Epcam⁺ cells were MACS sorted and plated on Alvetex scaffold inserts as
772 described above. 7 days after plating the whole scaffold was collected, washed with PBS and
773 incubated in blocking solution (10% goat serum in PBS) for 1 h at room temperature. Next,
774 the samples were incubated with a conjugated anti-CD104-eFluor660 antibody (1:100 in PBS
775 with 1:10 FcR blocking (Miltenyi Biotec, Germany)) for 1 h at room temperature. Then, the
776 samples were fixed with 4% PFA in PBS for 10 min and mounted with Vectashield Mounting
777 Medium with DAPI. Pictures were captured with the Axio Scan.Z1 slide scanner (Zeiss,
778 Germany).

779 **Lung organoid staining.** Cultured colonies were fixed with 4% PFA in PBS for 2-4 h at room
780 temperature followed by immobilization with Histogel (ThermoFisher Scientific, USA) for
781 paraffin embedding. At least five step sections (20 µm apart) per individual well were stained.
782 Fluorescence images were acquired using a confocal microscope Leica TCS SP5 (Leica
783 Microsystems, Germany). All the images were further processed with Fiji software.

784 **TTF1 and Ki67 co-staining.** Target retrieval solution pH9 (Agilent DAKO, USA) was used as
785 antigen retrieval. For histology, 1h incubation at room temperature with mouse anti-TTF1 was
786 followed by 45 min incubation at room temperature with secondary biotinylated-conjugated
787 antibodies. Next, the VECTASTAIN Elite ABC kit (Vector Laboratories, USA) was used
788 according to the manufacturer's instructions. The visualization of cell nuclei was performed
789 with hematoxylin and analysis employed the Nikon Eclipse 90i light microscope and NIS-
790 elements software. For immune-fluorescence, 1h incubation at room temperature with mouse
791 anti-TTF1 and rabbit anti-Ki67 was followed by 45 min incubation at room temperature with
792 anti-mouse AlexaFluor 555 and anti-rabbit AlexaFluor 488 (both secondary antibodies were

793 purchased from ThermoFisher Scientific (USA) and used at 1:250). Next, the slides were
794 incubated with Sudan Black B for 20 min and mounted with Vectashield Mounting Medium
795 with DAPI (Vector Laboratories, USA).

796 All pictures were captured with either a Zeiss Upright710 confocal microscope or a Zeiss
797 Upright780 confocal microscope unless differently stated.

798

799

800 **Quantitative real time PCR**

801 RNA preparation was performed using the MagMax-96 Total RNA Isolation Kit. cDNA
802 synthesis was performed using a SuperScript III First-Strand Synthesis System
803 (ThermoFisher Scientific, USA), according to the manufacturer's protocol. Quantitative real-
804 time PCR samples were prepared with 50-100 ng total cDNA for each PCR reaction. The
805 PCR, data collection and data analysis were performed on a 7500 FAST Real-Time PCR
806 System (ThermoFisher Scientific, USA). GAPDH was used as internal expression reference.

807

808 **Anti-Wisp1 treatment *in vivo***

809 BALB/cJ female mice (6 - 8 weeks old) were administered with anti-Wisp1 (5µg AF1680 and
810 5µg MAB1680, R&D, USA) or a control-IgG antibody via an intra-tracheal injection
811 (50µl/mouse). The following day, mice were intravenously injected with 250,000 4T1 cells.
812 Anti-Wisp1/control-IgG treatment was repeated daily, via a second intra-tracheal injection on
813 day 4, and intra-peritoneal injections on days 2,3,5 and 6. Mice were harvested 7 days after
814 the first treatment and lungs were embedded, cut and H&E stained. The lung metastatic
815 burden was assessed by counting number of metastases on four levels (100µm interval) from
816 two lung lobes (n=10 per group).

817

818 **EdU *in vitro* proliferation assay**

819 MMTV-PyMT actin-GFP cells were seeded at a density of 10,000 cells per well into collagen
820 solution coated 6-well plates. The following day, Ly6G⁺ lung cells and/or Epcam⁺ lung cells
821 were isolated via MACS sorting and added to the wells at a density of 100,000 cells/well. After
822 60h, wells were supplemented with 20 µM EdU (5-ethynyl-2'-deoxyuridine). Cells were
823 harvested 6h later, and EdU incorporation was assessed using the Click-iT Plus EdU Flow
824 Cytometry Assay Kit (ThermoFisher Scientific, USA), according to the manufacturer's
825 instructions. Sample data were acquired on a BD LSR-Fortessa flow cytometer and analysed
826 using FlowJo 10 software.

827

828

829

830 **Conditioned media preparation and vesicles isolation**

831 4T1-sLP-mCherry-GFP cells (Labelling-4T1) were plated on 10cm petri dishes. When cells
832 were 80-90% confluent, 7 mL of DMEM with 10% FCS was added to be conditioned for 24 h.
833 The conditioned media preparation and vesicles isolation were performed as previously
834 described³¹. Briefly, the media was collected and spun at 300g for 10 min. Next, the
835 supernatant was collected and spun at 2,000g for 10 min. The supernatant after this second
836 centrifugation was collected and used as conditioned media. For vesicles isolation, the
837 conditioned media was subsequently ultra-centrifuged at 10,000g for 30 min and at 100,000g
838 for 70 min. The vesicle pellet at this stage was washed with PBS, spun at 100,000g for 70 min
839 and resuspended again in PBS for *in vitro* uptake experiments.

840

841 **ImageStream analysis**

842 Image stream analyses were carried out on an ImageStream Mark X II Imaging Flow
843 Cytometer (Amnis Merck, USA). The acquired data were analysed using IDEA software
844 (Amnis Merck, USA).

845

846 **Electron Microscopy (EM)**

847 Experiments were performed on glass bottom dishes with a numbered grid (MatTek, USA) to
848 enable subsequent location of the same cell imaged by confocal microscopy. After confocal
849 imaging, cells were fixed in 8% formaldehyde in 0.1 M phosphate buffer (pH 7.4) added in
850 equal quantities to cell media for 15 min and then further fixed in 2.5% glutaraldehyde and 4%
851 formaldehyde in 0.1 M phosphate buffer (pH 7.4) for 1 h and then processed using the National
852 Center for Microscopy and Imaging Research (NCMIR) protocol (Deerinck, T.J., et al., NCMIR
853 methods for 3D EM: a new protocol for preparation of biological specimens for serial block
854 face scanning electron microscopy. National Center for Microscopy and Imaging Research
855 (2010) (available from <https://ncmir.ucsd.edu/sbem-protocol>).

856 For transmission electron microscopy (TEM), 70 nm serial sections were cut using a UC6
857 ultramicrotome (Leica Microsystems, Germany) and collected on formvar-coated slot grids.
858 No post-staining was required due to the density of metal deposited using the NCMIR protocol.
859 Images were acquired using a 120 kV Tecnai G2 Spirit TEM (FEI Company ThermoFisher
860 Scientific, USA) and an Orius CCD camera (Gatan, USA).

861

862 **RNA sequencing sample preparation**

863 **Bulk RNA sequencing:** CD45⁺Ter119⁻ (CD45-ve) cells were sorted from single cell
864 suspensions of metastatic lungs stained with anti-mouse CD45 and Ter119 antibodies and
865 DAPI. RNA isolation was performed using the MagMax-96 Total RNA Isolation Kit
866 (ThermoFisher Scientific, USA) that allows high quality RNA extraction from samples with low

867 cell numbers (<10,000 cells). RNA quality for each sample was assessed using the Agilent
868 RNA 6000 Pico Kit (Agilent Technologies, USA). RNA was amplified and analysed at the Barts
869 and London Genome Centre.

870 **Single cell RNA sequencing:** CD45⁺Ter119⁻ cells were sorted from single cell suspensions
871 of metastatic lungs stained with anti-mouse CD45 and Ter119 antibodies and DAPI. Library
872 generation for 10× Genomics were performed following the Chromium Single Cell 3' Reagents
873 Kits (10X Genomics, USA) and sequenced on an Hiseq4000 (Illumina, USA), to achieve an
874 average of 50,000 reads per cell.

875

876 **Determination of intracellular ROS levels**

877 Single cell suspensions from mouse lungs were incubated with mouse FcR Blocking Reagent
878 for 5 min on ice and subsequently incubated with CellROX® Deep Red Reagent
879 (ThermoFisher Scientific, USA) for 30 min at 37°C following manufacturer's recommendations.
880 Next, cells were washed twice with MACS buffer, stained with DAPI and analysed by flow
881 cytometry.

882

883 **Quantitative proteomic analysis of Ly6G cells**

884 Neutrophils were FACS-sorted from single cell suspensions of metastatic lungs stained with
885 a conjugated anti-mouse Ly6G-APC antibody (4 samples from independent sorts). Ly6G cells
886 from the metastatic niche (Ch⁺) and the distal lung (Ch⁻) were digested into peptides using a
887 previously described protocol (<https://doi.org/10.1101/220343>) and analysed by Data
888 Independent Acquisition (DIA) mass spectrometry³² on a Orbitrap Fusion Lumos instrument
889 (ThermoFisher Scientific, USA). A hybrid spectral library was generated using the search
890 engine Pulsar in Spectronaut Professional+ (version 11.0.15038, Biognosys AG, Switzerland)
891 by combing Data Dependent Acquisition (DDA) runs obtained from a pooled sample of Ly6G
892 cells, and the DIA data. Data analysis and differential protein expression was performed using
893 Spectronaut Professional+. A detailed description of sample processing, data acquisition and
894 processing are provided upon request.

895

896 **Bioinformatic analysis**

897 **Bulk RNA sequencing:** the sequencing was performed on biological triplicates for each
898 condition generating approximately 35 million 76bp paired end reads. The RSEM package
899 (version 1.2.29)³³ and Bowtie2 were used to align reads to the mouse mm10 transcriptome,
900 taken from known Gene reference table available at UCSC (<https://genome.ucsc.edu/>). For
901 RSEM, all parameters were run as default except "--forward-prob" which was set to "0.5".
902 Differential expression analysis was carried out with DESeq2 package³⁴ (version 1.12.4) within
903 R version 3.3.1 (<https://www.r-project.org/>). Genes were considered to be differentially

904 expressed if the adjusted p value was less than 0.05. Differentially expressed genes were
905 taken forward and their pathway and process enrichments were analysed using Metacore
906 (<https://portal.genego.com>).

907 Gene Set Enrichment Analysis, GSEA, (version 2.2.3)^{35,36} was carried out using ranked gene
908 lists using the Wald statistic and the gene sets of C2 canonical pathways and C5 biological
909 processes. All parameters were kept as default except for enrichment statistic (classic) and
910 max size which was changed to 5000 respectively. Gene signatures with FDR q-value equal
911 or less than 0.05 were considered statistically significant.

912 Heatmaps of differentially expressed genes were generated using the gplots (Gregory et al.,
913 gplots: Various R Programming Tools for Plotting Data. R package version 3.0.1. (2016).
914 <https://CRAN.R-project.org/package=gplots>) CRAN package (version 3.0.1). Genes were
915 clustered using an Eisen distance matrix and average linkage clustering.

916 **Single cell RNA sequencing:** raw reads were initially processed by the Cell Ranger v2.1.1
917 pipeline, using STAR (v2.5.1b) to align to the mm10 transcriptome, deconvolve reads to their
918 cell of origin using the UMI tags and report cell-specific gene expression count estimates. All
919 subsequent analyses were performed in R-3.4.1 using the cellrangerRkit, monocle and
920 pheatmap packages. Genes were considered to be “expressed” if the estimated (\log_{10}) count
921 was at least 0.1. Primary filtering was then performed by removing from consideration: genes
922 expressed in fewer than 20 cells; cells expressing fewer than 50 genes; cells for which the
923 total yield (i.e. sum of expression across all genes) was more than 2 standard deviations from
924 the mean across all cells in that sample; cells for which mitochondrial genes made up greater
925 than 10% of all expressed genes. PCA decomposition was performed and, after consideration
926 of the eigenvalue “elbow-plots”, the first 25 components were used to construct t-SNE plots
927 for both samples. Niche cells expressing Epcam were subdivided into those also expressing
928 Cdh1 and those not expressing Cdh1. Other genes expressed in at least 50% of cells in a
929 given group were said to be co-expressed and the set of genes co-expressed in one or more
930 groups was presented as a heatmap, with the columns (cells) clustered using the standard
931 Euclidean hierarchical method.

932

933 **Antibodies**

ANTIBODY	COMPANY	CATALOGUE No	CLONAL (CLONE)	DILUTION (TECHNIQUE)
Acetylated-tubulin	Sigma-Aldrich	T7451	Mouse monoclonal (6-11B-1)	1:1000 (IF)
CC10 (SCGB1A1)	Santa Cruz	sc-25555	Rabbit polyclonal (FL-96)	1:200 (IF)
CD11b-APC	Biologend	10121	Rat monoclonal (M1/70)	1:100 (FC)
CD11b-APCCy7	Biologend	101226	Rat monoclonal (M1/70)	1:100 (FC)
CD45-BV421	Biologend	103133	Rat monoclonal (30-F11)	1:200 (FC)
CD45-APC	eBioscience	17-0451-83	Rat monoclonal (30-F11)	1:200 (FC)
CD45-APC-eFluor780	eBioscience	47-0451-82	Rat monoclonal (30-F11)	1:200 (FC)
CD49f-PerCP-eFluor710	eBioscience	46-0495-82	Rat monoclonal (ebioGOH3)	1:200 (FC)
CD104-eFluor660	eBioscience	50-1049-82	Rat monoclonal (439-9b)	1:100 (FC; IF)
CD326(EPCAM)-APC	eBioscience	17-5791-81	Rat monoclonal (G8.8)	1:200 (FC)
CD326(EPCAM)-APC750Fire	Biologend	118230	Rat monoclonal (G8.8)	1:200 (FC)
E-CADHERIN	Abcam	Ab11512	Rat monoclonal (DECMA-1)	1:200 (IF)
GFP	Abcam	ab6673	Goat polyclonal	1:300 (IF)
HOPX	Santa Cruz	sc-30216	Rabbit polyclonal (FL-73)	1:250 (IF)
Ki67	Abcam	Ab16667	Rabbit monoclonal (SP6)	1:300 (IF)
Ly6A/E(SCA-1)-APC	Biologend	108111	Rat monoclonal (D7)	1:200 (FC)
Ly6A/E(SCA-1)-APC750Fire	Biologend	127652	Rat monoclonal (D7)	1:200 (FC)
Ly6A/E(SCA-1)-BV786	BD Bioscience	563991	Rat monoclonal (D7)	1:200 (FC)
Ly6G-APC	BD Bioscience	560599	Rat monoclonal (1A8)	1:150 (FC)
Ly6G-APC750Fire	Biologend	127652	Rat monoclonal (1A8)	1:150 (FC)
Ly6G-V450	BD Bioscience	560603	Rat monoclonal (1A8)	1:150 (FC)
mCHERRY	Abcam	ab183628	Rabbit polyclonal	1:750 (IF)
SOX2	eBioscience	14-9811-80	Rat monoclonal (Btjce)	1:500 (IF)
SP-C	Santa Cruz	sc-7706	Goat polyclonal (M-20)	1:200 (IF tissue)
TER-119	Biologend	116233	Rat monoclonal (TER-119)	1:200 (FC)
TTF1	DAKO	M3575	Mouse monoclonal (8G7G3/1)	1:50 *IF)
WISP1	Abcam	Ab178547	Rabbit polyclonal	1:100 (IF)

934

935 **Methods references**

936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966

25. Guy, C. T., Cardiff, R. D. & Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. *Mol. Cell. Biol.* **12**, 954–961 (1992).
26. Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T. & Nishimune, Y. 'Green mice' as a source of ubiquitous green cells. *FEBS Letters* **407**, 313–319 (1997).
27. Rock, J. R. *et al.* Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. *Proc Natl Acad Sci USA* **108**, E1475–83 (2011).
28. Srinivas, S. *et al.* Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. *BMC Dev. Biol.* **1**, 4 (2001).
29. Rawlins, E. L. *et al.* The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. *Cell Stem Cell* **4**, 525–534 (2009).
30. Lee, J.-H. *et al.* Anatomically and Functionally Distinct Lung Mesenchymal Populations Marked by Lgr5 and Lgr6. *Cell* **170**, 1149–1156.e12 (2017).
31. Théry, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. *Curr Protoc Cell Biol* **Chapter 3**, Unit 3.22–3.22.29 (2006).
32. Bruderer, R. *et al.* Optimization of Experimental Parameters in Data-Independent Mass Spectrometry Significantly Increases Depth and Reproducibility of Results. *Mol. Cell Proteomics* **16**, 2296–2309 (2017).
33. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinformatics* **12**, 323 (2011).
34. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
35. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 15545–15550 (2005).
36. Mootha, V. K. *et al.* PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat Genet* **34**, 267–273 (2003).